David Kirske - 29 Sep 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
EVP, Chief Financial Officer
Signature
David Kirske
Issuer symbol
N/A
Transactions as of
29 Sep 2022
Net transactions value
-$718,991
Form type
4
Filing time
03 Oct 2022, 18:26:58 UTC
Previous filing
20 Sep 2022
Next filing
06 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $759 +800 +4.7% $0.9489 17,713 29 Sep 2022 Direct
transaction CTIC common stock Sale $4,800 -800 -4.5% $6.00 16,913 29 Sep 2022 Direct F1
transaction CTIC common stock Options Exercise $94.89 +100 +0.59% $0.9489 17,013 29 Sep 2022 Direct
transaction CTIC common stock Sale $601 -100 -0.59% $6.01 16,913 29 Sep 2022 Direct F1
transaction CTIC common stock Options Exercise $132,695 +139,841 +827% $0.9489 156,754 30 Sep 2022 Direct
transaction CTIC common stock Sale $845,549 -139,841 -89% $6.05 16,913 30 Sep 2022 Direct F1, F2
transaction CTIC common stock Options Exercise $285 +300 +1.8% $0.9489 17,213 03 Oct 2022 Direct
transaction CTIC common stock Sale $1,875 -300 -1.7% $6.25 16,913 03 Oct 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -800 -0.17% $0.000000 466,608 29 Sep 2022 Common Stock 800 $0.9489 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -100 -0.02% $0.000000 466,508 29 Sep 2022 Common Stock 100 $0.9489 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -139,841 -30% $0.000000 326,667 30 Sep 2022 Common Stock 139,841 $0.9489 Direct F3
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -300 -0.09% $0.000000 326,367 03 Oct 2022 Common Stock 300 $0.9489 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.